ଇବ୍ରୁଟିନିବ

ଇବ୍ରୁଟିନିବ
Clinical data
Trade names	Imbruvica, others
Synonyms	PCI-32765, CRA-032765
AHFS/Drugs.com	monograph
MedlinePlus	a614007
data	EU EMA: yes; US DailyMed: Ibrutinib;
Pregnancy; category	AU: D ;
Routes of; administration	By mouth (capsules)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Protein binding	97.3%
Metabolism	Liver (CYP3A & CYP2D6)
Elimination half-life	4–6 hours
Excretion	Feces (80%), urine (10%)
Identifiers
	IUPAC name 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one;
ECHA InfoCard	100.232.543
Chemical and physical data
Formula	C25H24N6O2
Molar mass	୪୪୦.୫୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N;
	InChI InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1; Key:XYFPWWZEPKGCCK-GOSISDBHBU;

ଇବ୍ରୁଟିନିବ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଇମ୍ବ୍ରୁଭିକା, ହେଉଛି ଏକ ଔଷଧ ଯାହା ମାଣ୍ଟଲ ସେଲ ଲିମ୍ଫୋମା (ଏମସିଏଲ/MCL), କ୍ରୋନିକ୍ ଲିମ୍ଫୋସାଇଟିକ ଲ୍ୟୁକେମିଆ (ସିଏଲଏଲ/CLL) ଏବଂ ୱାଲଡେନଷ୍ଟ୍ରୋମର ମାକ୍ରୋଗ୍ଲୋବୁଲିନେମିଆ ରୋଗମାନଙ୍କର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ^[୫] ଏମସିଏଲ ଓ ସିଏଲଏଲ ରୋଗରେ ଅନ୍ୟ ସମସ୍ତ ଚିକିତ୍ସା ବିଫଳ ହେଲେ ଏହି ଔଷଧ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ଗ୍ରାଫ୍ଟ ବନାମ ହୋଷ୍ଟ ରୋଗରେ ମଧ୍ୟ ଏହି ଔଷଧ ଦିଆଯାଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଥ୍ରୋମ୍ବୋସାଇଟୋପେନିଆ, ନିମ୍ନ ଲୋହିତ ରକ୍ତ କଣିକା ସ୍ତର, କମ୍ ଶ୍ୱେତ ରକ୍ତ କଣିକା ସ୍ତର, ତରଳ ଝାଡ଼ା, ରାସ, ରକ୍ତସ୍ରାବ ଏବଂ ପାଟି ପ୍ରଦାହ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, ହୃଦ୍‌ପାତ, ଉଚ୍ଚ ରକ୍ତଚାପ, ଅନ୍ୟାନ୍ୟ କର୍କଟ ଏବଂ ଟ୍ୟୁମର ଲାଇସିସ୍ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୪] ଏହା ବ୍ରୁଟନ‌ର ଟାଇରୋସିନ୍ କାଇନେଜକୁ (BTK) ଅବରୋଧ କରି କାମ କରେ ଯାହାଦ୍ୱାରା ବି ସେଲ୍ ବିଭାଜନ ମନ୍ଥର ହୋଇଯାଏ ।^[୫]

ବା୨୦୧୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୪ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଇବ୍ରୁଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୫] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଉଲ୍ଲେଖ ଅଛି । ^[୭] ଜେନେରିକ୍ ସଂସ୍କରଣଗୁଡିକ ଅନୁମୋଦିତ ହୋଇଛି ।^[୮] ଯୁକ୍ତରାଜ୍ୟରେ 4 ସପ୍ତାହ ଚିକିତ୍ସା ବାବଦ ଖର୍ଚ୍ଚ ୨୦୨୧ ସୁଦ୍ଧା ୫,୦୦୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୪,୫୦୦ ଡଲାର ଅଟେ ।^[୧୦]

ଆଧାର

↑ "Ibrutinib (Imbruvica) Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
↑ "Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2020. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
↑ "UK Ibrutinib label". UK Electronic Medicines Compendium. 25 August 2016. Archived from the original on 30 July 2019. Retrieved 3 October 2021.
1 2 3 4 5 6 7 "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Archived from the original on 12 August 2020. Retrieved 21 April 2020.
1 2 3 4 5 "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Archived from the original on 10 April 2021. Retrieved 14 July 2021.
↑ "Ibrutinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 10 July 2020. Retrieved 24 November 2021.
↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
↑ "Ibrutinib: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 24 June 2021. Retrieved 19 June 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1028. ISBN 978-0857114105.
↑ "Imbruvica Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 September 2021. Retrieved 24 November 2021.

[Drugs.com_pregnancy-1] "Ibrutinib (Imbruvica) Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 28 March 2020. Retrieved 28 March 2020.

[2] "Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2020. Archived from the original on 28 March 2020. Retrieved 28 March 2020.

[UKlabel2016-3] "UK Ibrutinib label". UK Electronic Medicines Compendium. 25 August 2016. Archived from the original on 30 July 2019. Retrieved 3 October 2021.

[PI2021-4] 1 2 3 4 5 6 7 "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Archived from the original on 12 August 2020. Retrieved 21 April 2020.

[EPAR2021-5] 1 2 3 4 5 "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Archived from the original on 10 April 2021. Retrieved 14 July 2021.

[6] "Ibrutinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 10 July 2020. Retrieved 24 November 2021.

[WHO22nd-7] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[8] "Ibrutinib: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 24 June 2021. Retrieved 19 June 2021.

[BNF81-9] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1028. ISBN 978-0857114105.

[10] "Imbruvica Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 13 September 2021. Retrieved 24 November 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]